US 11,952,634 · Application 17/523,235 · Granted Apr 9, 2024
US 11,952,634
Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
Estimated expiration
December 8, 2035
9y 71d remaining
Earliest effective filing
Dec 8, 2015
+ 20 years
Dec 8, 2035
PTA +123d
Apr 9, 2036
TD cap (US 11,186,876)
Dec 8, 2035
Final
Dec 8, 2035
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- November 10, 2021
- Earliest effective filing
- December 8, 2015
- Issue date
- April 9, 2024
- PTA
- +123 days
- Base expiry (before PTA)
- December 8, 2035
December 8, 2015 + 20 years = December 8, 2035 + 123 PTA days = April 9, 2036
- Continuation of application 16/215,340, filed Dec 10, 2018, issued as US 11,186,876
- Continuation of application 14/962,864, filed Dec 8, 2015, issued as US 10,196,693
- Continuation of application 14/962,864, filed Dec 8, 2015, issued as US 10,196,693
- PRO62/091,195 — Provisional — not used for base term
- PRO62/142,504 — Provisional — not used for base term
- PRO62/167,110 — Provisional — not used for base term
- PRO62/091,195 — Provisional — not used for base term
- PRO62/142,504 — Provisional — not used for base term
- PRO62/167,110 — Provisional — not used for base term
- PRO62/091,195 — Provisional — not used for base term
- PRO62/142,504 — Provisional — not used for base term
- PRO62/167,110 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to December 8, 2035 (earliest expiring referenced patent: US 11,186,876)
US 9,636,000
Could not resolve calculation details
US 11,186,876· Application 16/215,340Capping patent
Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
- Filing date
- Dec 10, 2018
- Earliest effective filing
- Dec 8, 2015
- Issue date
- Nov 30, 2021
- PTA
- 0 days
- Calculated expiration
- Dec 8, 2035
Continuation of 14/962,864, filed Dec 8, 2015, issued as US 10,196,693
Dec 8, 2015 + 20y = Dec 8, 2035
US 10,196,693· Application 14/962,864
Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
- Filing date
- Dec 8, 2015
- Earliest effective filing
- Dec 8, 2015
- Issue date
- Feb 5, 2019
- PTA
- 0 days
- Calculated expiration
- Dec 8, 2035
Dec 8, 2015 + 20y = Dec 8, 2035
US 11,952,634· Application 17/523,235(from application 17/523,235)
Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
- Filing date
- Nov 10, 2021
- Earliest effective filing
- Dec 8, 2015
- Issue date
- Apr 9, 2024
- PTA
- +123 days
- Calculated expiration
- Apr 9, 2036
Continuation of 16/215,340, filed Dec 10, 2018, issued as US 11,186,876
Continuation of 14/962,864, filed Dec 8, 2015, issued as US 10,196,693
Continuation of 14/962,864, filed Dec 8, 2015, issued as US 10,196,693
Dec 8, 2015 + 20y + 123d PTA = Apr 9, 2036
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/523,235 · US 11,952,634
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,952,634: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11952634Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.